Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15544218 | 0.91 | GUSB (0.42) | GUSBEGFRERBB2TYMSCA1 | |
| SCHEMBL15545223 | 0.87 | EGFR (0.44) | GUSBEGFRERBB2TYMSCA1 | |
| SCHEMBL15544617 | 0.86 | GUSB (0.44) | GUSBEGFRERBB2CA1CA2 | |
| SCHEMBL15544800 | 0.85 | HPGD (0.32) | CA1CA2GAASMN1; SMN2MEN1 | |
| SCHEMBL16342580 | 0.85 | ALDH1A1 (0.33) | CA1CA2ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL15544042 | 0.81 | PKM (0.38) | CA1CA2ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL15607813 | 0.80 | GUSB (0.44) | GUSBEGFRERBB2ALDH1A1MAPK1 | |
| SCHEMBL16367303 | 0.79 | MAPK1 (0.49) | GUSBCA1CA2CA9CA12 | |
| SCHEMBL15544940 | 0.78 | GUSB (0.50) | GUSBEGFRERBB2TYMSCA1 | |
| SCHEMBL16367387 | 0.78 | GUSB (0.50) | GUSBEGFRERBB2TYMSCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
| EP-2793871-A1 | COMPOUNDS AND METHODS FOR SELECTIVE IMAGING AND/OR ABLATION | Auckland Uniservices Limited (NZ) | 2014-10-29 | — | — | EP | disclosed |
| WO-2014007650-A1 | COMPOUNDS AND METHODS FOR SELECTIVE IMAGING AND/OR ABLATION | AUCKLAND UNISERVICES LIMITED (NZ) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | GUSB 86/4885EGFR 1866/4885ERBB2 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.